Overweight and obesity management strategies in survivors of paediatric acute lymphoblastic leukaemia: a systematic review protocol.
Overweight and obesity management strategies in survivors of paediatric acute lymphoblastic leukaemia: a systematic review protocol.
复制标题
DOI：
10.1136/bmjopen-2018-022530
复制
发表时间：
2018-06-22
期刊：
影响因子：
2.9
通讯作者：
Samaan MC
中科院分区：
文献类型：
--
作者：
Ladhani S;Empringham B;Wang KW;Portwine C;Banfield L;de Souza RJ;Thabane L;Samaan MC
急性淋巴细胞白血病是最常见的儿科癌症。儿童急性淋巴细胞白血病（萨尔）的幸存者有肥胖和相关心脏代谢疾病的风险，包括2型糖尿病，高血压，中风和心血管事件。因此，解决该人群的肥胖问题非常重要，因为这可能有助于减轻未来的心脏代谢合并症。在这篇系统性综述中，我们的目的是评估目前的治疗策略，包括生活方式干预，药物治疗和减肥手术，以管理超重和肥胖的萨尔。我们将检索以下数据库中的主要研究：CINAHL、SPORTDiscus、EMBASE、MEDLINE、PsycINFO、科克伦对照试验中心注册库和科克伦系统评价数据库。此外，将在ClinicalTrials.gov以及会议记录、演示文稿、摘要、社论和ProQuest论文和论文A&I中检索未发表的主要研究。评审员将独立进行标题、摘要和全文筛选以及数据提取和偏倚风险评估，并咨询第三位评审员以解决分歧。测试将运行和更新到2018年5月1日。证据的总体质量将使用每个结局的建议、评估、开发和评价标准的分级来确定。如果识别出两项采用类似干预措施、人群、设计和结局的研究，则将进行荟萃分析。由于不会包含个体患者数据，因此我们不需要伦理批准。这篇综述将发表在同行评审期刊上。CRD 42016051031。
Acute lymphoblastic leukaemia is the most common paediatric cancer. Survivors of childhood acute lymphoblastic leukaemia (SALL) are at risk of obesity and related cardiometabolic diseases including type 2 diabetes, hypertension, stroke and cardiovascular events. Therefore, it is important to address obesity in this population as this may help mitigate future cardiometabolic comorbidities. In this systematic review, we aim to assess current treatment strategies including lifestyle interventions, pharmacotherapy and bariatric surgery to manage overweight and obesity in SALL. We will search the following databases for primary studies: CINAHL, SPORTDiscus, EMBASE, MEDLINE, PsycINFO, Cochrane Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews. In addition, unpublished primary studies will be searched in ClinicalTrials.gov as well as conference proceedings, presentations, abstracts, editorials and ProQuest Dissertations and Theses A&I. Reviewers will perform title, abstract, and full-text screening as well as data abstraction and risk of bias assessment independently with a third reviewer to be consulted to resolve disagreements. Searches will be run and updated through May 1st, 2018. The overall quality of the evidence will be determined using the Grading of Recommendations, Assessment, Development, and Evaluation criteria for each outcome. A meta-analysis will be performed if two studies deploying similar interventions, populations, and design and outcomes are identified. As individual patient data will not be included, we do not require ethics approval. This review will be published in a peer-reviewed journal. CRD42016051031.
登录
查看更多内容
DOI：
10.1136/bmj.b2535
发表时间：
2009-07-21
期刊：
BMJ (Clinical research ed.)
影响因子：
--
作者：
Moher D;Liberati A;Tetzlaff J;Altman DG;PRISMA Group
通讯作者：
PRISMA Group
DOI：
10.1097/01.mph.0000181428.63552.e9
发表时间：
2005-09-01
影响因子：
1.2
作者：
Kourti, M;Tragiannidis, A;Athanassiadou, F
通讯作者：
Athanassiadou, F
影响因子：
45.3
作者：
Oeffinger, Kevin C.;Adams-Huet, Beverley;Vega, Gloria Lena
通讯作者：
Vega, Gloria Lena
影响因子：
2.9
作者：
Ried-Larsen, Mathias;Christensen, Robin;Karstoft, Kristian
通讯作者：
Karstoft, Kristian
影响因子：
45.3
作者：
Garmey, Edward G.;Liu, Qi;Oeffinger, Kevin C.
通讯作者：
Oeffinger, Kevin C.